New information released by the United Kingdom’s Medicines and Healthcare products Regulatory Agency reveals:
…Up to and including 5th May 2021 that we have received 644 Adverse Drug Reaction (ADR) reports associated with all COVID-19 vaccinations from The Isle of Man. The total number of reports received from The Isle of Man are contained within the Coronavirus weekly summaries under England, however, are not currently routinely separated.
The accuracy of the data provided relies on the postcode being provided by the reporter on the original Yellow Card which is associated to the Isle of Man Health Authority. Furthermore, if the postcode is incorrectly provided, the Yellow Card will not be included in this analysis. Also, if the reporter has only provided their email address that report will also not be included.Freedom of Interest request on the number of yellow card reports from the Isle of Man (FOI 21-401)
The MHRA goes to some length to clarify that this information is subject to a number of disclaimers, including:
It is important to bear in mind the following points when interpreting Yellow Card data:
• Reports are also received by the MHRA from pharmaceutical companies who have a legal obligation to report serious suspected ADRs relating to their products. This information should only be used for education and promotion and not be used for audit purposes.
• Please be aware, the reporting of a particular reaction does not necessarily mean that it has been caused by a drug or vaccine. Many factors must be considered in assessing the relationship between a drug or vaccine and suspected reaction including the possible contribution of other drugs being taken, and the underlying disease.
• Furthermore, the number of reports received should not be used as a basis for determining incidence of a reaction as neither the total number of reactions occurring, nor the number of patients using a drug or vaccine is included in this data.Freedom of Interest request on the number of yellow card reports from the Isle of Man (FOI 21-401)